Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 2 sources · 24 days · First seen · Last updated
BioNTech and Merck pharmaceutical developments
Overview
BioNTech has experienced stock price increases driven by broader momentum in the mRNA and cancer research sector, following positive results from competitor Moderna. Despite this growth, BioNTech faces challenges including the discontinuation of a Phase 2 colorectal cancer vaccine study and the planned departure of its founders by the end of 2026.
BioNTech is currently transitioning into an oncology-focused company. While the firm reported a third-quarter net profit of €184.5 million, it recorded a net loss of €1.168 billion over the first nine months of the year due to research and development costs. The company has raised its 2026 revenue guidance to between €1.7 billion and €1.9 billion, supported by milestone and licensing payments from collaborations.
Concurrently, Merck & Co. is addressing the upcoming patent expirations for its oncology drug, Keytruda. To counter a projected revenue decline for the drug, Merck is expanding its non-oncology portfolio, which is forecasted to reach $29.9 billion by 2032.
Entities
BioNTech · GlobalData · Merck · Özlem Türeci · Moderna
Timeline
-
[BUSINESS] 2 sourcesMerck and BioNTech navigate shifting pharmaceutical landscapes
Merck prepares for Keytruda patent expirations by expanding non-oncology portfolios, while BioNTech shifts focus toward oncology amid high R&D costs and rising revenue guidance.
-
[BUSINESS] 6 sourcesBioNTech shares rise amid sector momentum from Moderna
BioNTech shares rose 5.4% amid sector optimism driven by Moderna’s successful cancer vaccine trials, despite BioNTech facing recent clinical setbacks and leadership transitions.
Sources
european-biotechnology.com · pyr.com